Literature DB >> 12671333

Scleroderma renal crisis.

L Michael Prisant1, Don H Loebl, Laura L Mulloy.   

Abstract

Abrupt onset of severe uncontrolled hypertension and rapidly progressive oliguric renal failure characterizes scleroderma renal crisis. The etiology is unclear, but very high renin levels are present. While scleroderma is more common in women and whites, there is no difference in the prevalence of scleroderma renal crisis by gender. However, there appears to be a higher prevalence of scleroderma renal crisis among African Americans than whites. Survival was dismal prior to the introduction of the vigorous treatment of hypertension and use of converting-enzyme inhibitors. However, most data on the benefit of these medications are derived from uncontrolled and unblinded studies. Prospective, randomized controlled trials are needed to assess the role of angiotensin receptor blockers. Prevention trials could define the role of various drugs in decreasing the rate of scleroderma renal crisis. Copyright 2003 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671333      PMCID: PMC8099293          DOI: 10.1111/j.1524-6175.2003.01928.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  Captopril hepatotoxicity in a case of renal crisis due to systemic sclerosis.

Authors:  J L Deira; L Corbacho; A Bondía; J L Lerma; A Gascón; B Martín; P García; J M Tabernero
Journal:  Nephrol Dial Transplant       Date:  1997-08       Impact factor: 5.992

2.  Control of hypertension and reversal of renal failure in scleroderma.

Authors:  P D Mitnick; P U Feig
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

3.  Successful medical treatment of scleroderma renal crisis.

Authors:  C Wasner; C R Cooke; J F Fries
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

4.  Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors.

Authors:  V D Steen; J P Costantino; A P Shapiro; T A Medsger
Journal:  Ann Intern Med       Date:  1990-09-01       Impact factor: 25.391

5.  Long-term outcomes of scleroderma renal crisis.

Authors:  V D Steen; T A Medsger
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

6.  The management of renal scleroderma: experience with dialysis, nephrectomy and transplantation.

Authors:  E C LeRoy; R M Fleischmann
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

7.  Failure of captopril to reverse the renal crisis of scleroderma.

Authors:  E A Brown; G A Macgregor; R N Maini
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

8.  Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients.

Authors:  H H Whitman; D B Case; J H Laragh; C L Christian; G Botstein; H Maricq; E C Leroy
Journal:  Arthritis Rheum       Date:  1982-03

9.  Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases.

Authors:  Y M Traub; A P Shapiro; G P Rodnan; T A Medsger; R H McDonald; V D Steen; T A Osial; S F Tolchin
Journal:  Medicine (Baltimore)       Date:  1983-11       Impact factor: 1.889

10.  Clinical course of patients with scleroderma renal crisis treated with captopril.

Authors:  E T Zawada; P J Clements; D A Furst; H A Bloomer; H E Paulus; M H Maxwell
Journal:  Nephron       Date:  1981       Impact factor: 2.847

View more
  1 in total

Review 1.  Pleiotropic Effects of Immune Responses Explain Variation in the Prevalence of Fibroproliferative Diseases.

Authors:  Shirley B Russell; Joan C Smith; Minjun Huang; Joel S Trupin; Scott M Williams
Journal:  PLoS Genet       Date:  2015-11-05       Impact factor: 5.917

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.